AI Article Synopsis
- Research shows that Alzheimer's Disease (AD) starts affecting the brain before any visible symptoms appear, making early detection crucial for effective treatment.
- Identifying reliable biomarkers, particularly in the cerebrospinal fluid (CSF), is key; three candidates have emerged: amyloid beta, total tau (t-tau), and phosphorylated tau (p-tau), which are promising for diagnosing AD and predicting it during mild cognitive impairment (MCI).
- A review of studies from 1993 to 2011 has been conducted to explore how these CSF biomarkers behave in cognitively healthy older adults, with ongoing evaluation of their predictive ability in this group.
Article Abstract
Numerous studies have shown that Alzheimer's Disease (AD) pathology begins before the onset of clinical symptoms. Because therapies are likely to be more effective if they are implemented early in the disease progression, it is necessary to identify reliable biomarkers to detect AD pathology in the early stages of the disease, ideally in presymptomatic individuals. Recent research has identified three candidate cerebrospinal fluid (CSF) biomarkers that reflect AD pathology: amyloid beta, total tau protein (t-tau), and tau protein phosphorylated at AD-specific epitopes (p-tau). They are useful in supporting the AD diagnosis and have predictive value for AD when patients are in the stage of mild cognitive impairment (MCI). However, their predictive utility in cognitively healthy subjects is still being evaluated. We conducted a review of studies published between 1993 and 2011 and summarized their findings on the role of CSF biomarkers for AD in healthy elderly.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904672 | PMC |
| http://dx.doi.org/10.2741/4170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!